Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-30 | 2024-03 | 2.53 | N/A | N/A | N/A |
2024-02-06 | 2023-12 | 2.47 | 2.49 | 0.02 | 0.81% |
2023-11-02 | 2023-09 | -0.08 | 0.1 | 0.18 | 225.00% |
2023-08-08 | 2023-06 | 1.98 | 2.11 | 0.13 | 6.57% |
2023-04-27 | 2023-03 | 1.73 | 1.62 | -0.11 | -6.36% |
2023-02-02 | 2022-12 | 1.83 | 2.09 | 0.26 | 14.21% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-10-08 | Wells Fargo | Upgrade | Overweight | Overweight |
2023-10-08 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-10-01 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Morgan Stanley | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-04-14 | ALVAREZ RALPH | Director | 54.03K | Stock Award(Grant) |
2024-02-11 | HAKIM ANAT | General Counsel | 30.48K | Stock Award(Grant) |
2024-04-14 | HEDLEY MARY LYNNE | Director | 1.58K | Stock Award(Grant) |
2024-04-14 | JOHNSON KIMBERLY H | Director | 2.63K | Stock Award(Grant) |
2024-02-15 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 98.90M | Sale |
2024-04-14 | LUCIANO JUAN R | Director | 15.68K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | Lilly Endowment, Inc | 99.98M | 53.70B | 10.53% |
2023-06-29 | Vanguard Group Inc | 69.92M | 32.79B | 7.37% |
2023-06-29 | Blackrock Inc. | 64.45M | 30.23B | 6.79% |
2023-06-29 | PNC Financial Services Group, Inc. | 51.87M | 24.33B | 5.46% |
2023-06-29 | State Street Corporation | 33.88M | 15.89B | 3.57% |
2023-06-29 | FMR, LLC | 32.80M | 15.38B | 3.46% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 26.65M | 12.50B | 2.81% |
2023-06-29 | Vanguard 500 Index Fund | 18.76M | 8.80B | 1.98% |
2023-06-29 | Vanguard/Primecap Fund | 13.35M | 6.26B | 1.41% |
2023-05-30 | Fidelity 500 Index Fund | 8.83M | 3.79B | 0.93% |
2023-08-30 | SPDR S&P 500 ETF Trust | 8.68M | 4.81B | 0.91% |
2023-08-30 | iShares Core S&P 500 ETF | 7.37M | 4.08B | 0.78% |
Dividend | Date |
---|---|
1.3 | 2024-02-15 |
1.3 | 2024-02-14 |
1.13 | 2023-11-14 |
1.13 | 2023-09-08 |
1.13 | 2023-08-14 |
1.13 | 2023-05-12 |
Split | Date |
---|---|
2 : 1 | 1997-10-16 |
2 : 1 | 1995-12-21 |
2 : 1 | 1989-05-01 |
2 : 1 | 1986-01-30 |
-
-
-
My hospital is pumping this med $LLY gonna be a billionaire beat
-
They know Sorrento is better and less dosage
-
But $SRNE has the most Potent cocktail
-
Hmmmm something is going to blow
-
Regeneron already has rights to it
-
Maybe lily owns the bar but sell srne?
-
But $SRNE has a better cocktail???????
-
$SRNE is a better product
-
-
-
-
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
-
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.Per NIH, here is the CORE issue with
Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT. That the efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
-
Forget Nvidia, These Unstoppable Stocks Are Better Buys
news.google.com • -
What You Need To Know Ahead of Eli Lilly's Earnings Report Tuesday
investopedia.com • -
LLY June 7th Options Begin Trading
news.google.com • -
MSN
news.google.com • -
Analysts Set Eli Lilly and Company (NYSE:LLY) Target Price at $728.05
news.google.com • -
Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.3%
news.google.com • -
Is Eli Lilly Stock A Buy After Weight-Loss Win In Sleep Apnea?
news.google.com • -
LLY vs. JNJ: Which Big Pharma Stock Is Better?- TipRanks
news.google.com • -
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
news.google.com • -
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
news.google.com • -
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
news.google.com • -
Eli Lilly and Company (LLY) to Release Quarterly Earnings on Tuesday
news.google.com • -
Eli Lilly (NYSE:LLY) Notches Up on New Manufacturing Plans- TipRanks
news.google.com • -
What You Can Learn From Eli Lilly and Company's (NYSE:LLY) P/S
news.google.com •